Little Support For Eli Lilly's High Valuation
https://seekingalpha.com/article/4722429-little-support-for-eli-lilly-high-valuation?source=feed_all_articles
Sep 20, 2024 - An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due to expensive valuation. See more.
0
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
https://www.fool.com/investing/2024/09/18/this-small-cap-stock-has-a-promising-glp-1-drug-wh/?source=iedfolrf0000001
Sep 18, 2024 - Terns has a modest market cap of less than $800 million, and its possible upside could be massive.
0
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
https://www.benzinga.com/markets/equities/24/09/40785056/zepbound-and-mounjaro-maker-eli-illy-has-a-new-cfo-as-it-navigates-regulatory-challenges-what-yo
Sep 09, 2024 -
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
0
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
https://www.fool.com/investing/2024/09/08/beyond-mounjaro-and-zepbound-eli-lilly/?source=iedfolrf0000001
Sep 08, 2024 - This drugmaker should have a basketful of growth drivers over the next decade.
0
Elis confirms takeover approach for Vestis
https://seekingalpha.com/news/4147820-elis-confirms-takeover-approach-for-vestis?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Sep 06, 2024 - Elis SA confirms preliminary takeover approach for uniform supplier Vestis Corp., potentially signaling M&A activity in the sector.
0
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
https://www.zacks.com/stock/news/2333037/eli-lilly-s-weekly-insulin-shot-meets-two-late-stage-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333037
Sep 06, 2024 - Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
0
Eli Lilly bets $409M for AI-focused drug discovery
https://seekingalpha.com/news/4147427-eli-lilly-bets-409m-for-ai-focused-drug-discovery?source=feed_sector_healthcare
Sep 05, 2024 - Eli Lilly (LLY) partners with Genetic Leap to develop gene-based therapeutics using AI-driven drug discovery, in a deal worth up to $409M. Read more here.
0
Eli Lilly marks late-stage trial win for once weekly insulin
https://seekingalpha.com/news/4147209-eli-lilly-marks-trial-win-once-weekly-insulin?source=feed_sector_healthcare
Sep 05, 2024 - Eli Lilly (LLY) stock will be in focus as two phase 3 trials for its once-weekly insulin efsitora alfa succeed against daily basal insulins. Read more here.
0
Eli Lilly’s quest for obesity drugs leads to $1B bet on dark genome
https://seekingalpha.com/news/4146895-eli-lilly-bets-up-1b-haya-deal-obesity?source=feed_sector_healthcare
Sep 04, 2024 - Eli Lilly (LLY) partners with Haya Therapeutics to develop drugs for obesity and metabolic diseases in a deal worth up to $1B. Read more here.
0
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
https://www.fool.com/investing/2024/08/31/these-3-factors-could-make-eli-lilly-stock-better-/?source=iedfolrf0000001
Aug 31, 2024 - This competitive showdown just saw one of the players hit a couple of bumps.
0